**Core tip:** This is the first study to examine the reliability and validity of the Chinese version of the EORTC QLQ-CR29 in patients with colorectal cancer in mainland China. The EORTC QLQ-CR29 exhibits high validity and reliability in Chinese patients with CRC, and can therefore be recommended as a valuable tool for the assessment of quality of life in these patients.

INTRODUCTION
============

Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer death worldwide. According to the latest data, almost 1.4 million people were diagnosed with CRC and 700000 people died of CRC worldwide in 2012\[[@B1]\]. Moreover, the number of newly diagnosed CRC patients in China in 2012 was estimated to be 331 300, which accounted for approximately 24% of all cases in the world\[[@B2]\]. Therefore, it is important to prolong the lives of CRC patients and improve their quality of life.

The EORTC QLQ-CR29 questionnaire was developed by the European Organization for Research and Treatment of Cancer (EORTC) to evaluate the quality of life in CRC patients. It has already been validated in Holland, Spain, Poland and several other countries\[[@B3]-[@B8]\]. However, the dietary and cultural differences between China and Western countries may lead to different interpretations of quality of life. Therefore, it is essential to test the reliability and validity of the Chinese version of the EORTC QLQ-CR29 in patients with CRC, which has never been done in mainland China.

MATERIALS AND METHODS
=====================

Patients
--------

A total of 356 patients with CRC in the Third Xiangya Hospital of Central South University, the Affiliated Tumor Hospital of Central South University, the Longgang Central Hospital of Shenzhen, and the Affiliated Tumor Hospital of Guangzhou Medical University were recruited between March 2014 and January 2015. Patients were included in the study if they were older than 18 years and had histological confirmation of colon or rectal cancer. Patients who had complications or who had been diagnosed with a cognitive disorder or psychonosema were excluded. All participants completed the Chinese version of the EORTC QLQ-C30 and EORTC QLQ-CR29 during the 11-mo recruitment period.

Instruments
-----------

**EORTC QLQ-C30:** The EORTC QLQ-C30 is the core questionnaire designed by the European Organization for Research and Treatment of Cancer, and has five functional dimensions: physical functioning (PF), role functioning (RF), cognitive functioning (CF), emotional functioning (EF) and social functioning (SF); three symptom scales: fatigue (FA), pain (PA), and nausea/vomiting (NV); six single items addressing various symptoms and perceived financial impact, and a global health-related quality of life (HRQOL) subscale. Among the 30 items, 29 have seven possible responses and are awarded a score of 1 to 7 points according to the answer; the other has a four-point answer scale: 1, Not at all; 2, A little; 3, Quite a bit; 4, Very much\[[@B9],[@B10]\]. The reliability and validity of C30 have already been verified in China\[[@B11]\].

**EORTC QLQ-CR29:** The EORTC QLQ-CR29 was specifically designed by the EORTC QL Group (The European Organization for Research and Treatment of Cancer Quality of Life Group) as the QLQ-C30 supplement for the evaluation of HRQOL in CRC patients. This combination has already been widely used in both clinical and basic research\[[@B12]-[@B14]\].

The QLQ-CR29 includes 29 items that evaluate symptoms (gastrointestinal, urinary, pain and others) and functional areas (sexual, body image and others) that are associated with CRC and its treatments. There are separate items for patients with and without a stoma (items 49 to 54, with item 55 only for patients with a stoma) and separate items to evaluate the sexual function of men and women. The questionnaires ask for all items in the past week except those pertaining to sexuality, which request the patients to evaluate the items in the past four weeks. Similar to the EORTC QLQ-C30, the QLQ-CR29 has a Likert scale of four response categories (item 48 requires a yes or no answer)\[[@B5],[@B8],[@B9]\]. All patient-rated scores are linearly converted into a scale from 0 to 100 for both the QLQ-C30 and QLQ-CR29\[[@B7],[@B15]\].

According to the EORTC guidelines\[[@B16]\], two translators first translated EORTC QLQ-CR29 into Chinese (Simplified Chinese), then another two translators translated the Chinese version of the EORCT QLQ-CR29 into English and compared it with the original questionnaire to verify whether it fully reflected the contents of the original questionnaire. After several amendments, we then selected 20 female and 20 male patients (both male and female patients included 3 stoma patients) to determine if the questionnaire was easy to understand. According to the feedback, we finally developed the Chinese version of the EORTC QLQ-CR29.

Karnofsky performance scale
---------------------------

The Karnofsky performance scale (KPS) was determined by physicians according to the condition of the patient with respect to illness, self-care ability and daily activities. The total score of 100 was graded by 10 and the higher the score, the better the patient's health\[[@B17],[@B18]\].

Ethics
------

Approval for this study was obtained from the Ethics Committees of the four participating hospitals. Before the investigation, we asked patients to provide a signed informed consent, and confirmed their consent to participate in the study to protect their voluntary participation, right to know, and right of privacy.

Statistical analysis
--------------------

We selected nurses on duty in the relevant departments as investigators in this study. After training, the investigators explained and introduced the protocol to the participants, and obtained basic information and KPS scores. Each participant completed the EORTC QLQ-CR29 and EORTC QLQ-C30 independently. Each scale score was converted based on standard formula, and the points ranged from 0 points (the worst) to 100 points (best).

All data were analyzed using SPSS17.0 software. Numbers (percentages) were used to describe numerical data and the mean ± SD was adopted to describe measured data.

The internal consistency of the questionnaire was assessed using Cronbach's α coefficient (α \> 0.7 was considered acceptable).

Multitrait scaling analysis was used to assess the module structure. The convergent validity of each item was determined by calculating the correlation between each item and its own dimension (*r* \> 0.40 was considered acceptable). For discriminant validity, we expected the correlation between each item and its own dimension to be greater than the correlation between the item and the other dimensions.

Correlations between all of the EORTC QLQ-CR29 and the EORTC QLQ-C30 areas were calculated based on the Spearman correlation coefficient (*r* \> 0.4 was considered strongly correlated).

Known-groups validity was assessed by making comparisons between subgroups based on the presence of a stoma and KPS score (KPS ≤ 80; KPS \> 80) using the Wilcoxon rank sum test.

The acceptability was evaluated by the completion ratio of the questionnaires and the miss rate of each item.

RESULTS
=======

Patient characteristics and compliance
--------------------------------------

A total of 356 patients were enrolled in the study and no one declined the invitation to participate. The study group included 213 men and 128 women with an average age of 54.5 (±13.5) years. Of the participants, 193 patients had colon cancer, 147 patients had rectal cancer and three had both colon and rectal cancer, and 102 patients had metastasis (Table [1](#T1){ref-type="table"}).

###### 

Sociodemographic and clinical characteristics of the patients (*n* = 356) *n* (%)

  **Characteristics**                                           **No. of patients[1](#T1FN1){ref-type="table-fn"}**
  ------------------------------------------------------------- -----------------------------------------------------
  Age (yr, mean ± SD)                                           54.5 ± 13.5
  Sex                                                           341[2](#T1FN2){ref-type="table-fn"}
  Male                                                          213 (62.5)
  Female                                                        128 (37.5)
  Educational status                                            341[2](#T1FN2){ref-type="table-fn"}
  Junior high school                                            182 (53.4)
  Senior high school                                            107 (31.4)
  University                                                    47 (13.8)
  Postgraduate and above                                        5 (1.5)
  Marital status                                                340[2](#T1FN2){ref-type="table-fn"}
  Single                                                        5 (1.5)
  Married                                                       334 (98.2)
  Divorced                                                      1 (0.3)
  Employment                                                    343[2](#T1FN2){ref-type="table-fn"}
  Yes                                                           268 (78.1)
  No                                                            75 (21.9)
  Location of tumor                                             342[2](#T1FN2){ref-type="table-fn"}
  Colon                                                         193 (56.4)
  Rectum                                                        147 (43.0)
  Both                                                          2 (0.6)
  Metastasis                                                    343[2](#T1FN2){ref-type="table-fn"}
  Yes                                                           102 (29.7)
  No                                                            215 (62.7)
  Unknown                                                       26 (7.6)
  Time from first diagnosis (wk) Median (interquartile range)   16.0 (33.8)

All percentages are valid;

There are missing data.

Reliability
-----------

**Internal consistency:** Reliability was assessed using Cronbach's α coefficient. The correlations between the items showed that the body image and stool frequency dimensions had high reliability (α \> 0.7), while the urinary frequency and blood and mucus in the stool dimensions had lower, but still moderate reliability (0.608 and 0.641). Except for the urinary frequency dimension (0.608 with *vs* 0.363 without), the reliability of other dimensions in patients without a stoma was higher than that in patients with a stoma (Table [2](#T2){ref-type="table"}).

###### 

Item convergent and discriminant validity for the EORTC QLQ-CR29 scales, and for patients with and without a stoma

  **QLQ-CR29 scales**        **Total sample (*n* = 354)[1](#T2FN1){ref-type="table-fn"}**   **Without a stoma (*n* = 298)**   **With a stoma (*n* = 56)**                                                                   
  -------------------------- -------------------------------------------------------------- --------------------------------- ----------------------------- ------------- ------------- ------- ------------- ------------- -------
  Urinary frequency          0.589-0.923                                                    0.004-0.306                       0.406                         0.588-0.924   0.002-0.321   0.363   0.587-0.919   0.017-0.333   0.608
  Blood or mucus in stools   0.794-0.886                                                    0.004-0.712                       0.641                         0.790-0.891   0.002-0.738   0.638   0.815-0.829   0.037-1.000   0.632
  Stool frequency            0.689-0.965                                                    0.003-0.641                       0.679                         0.696-0.967   0.001-0.669   0.716   0.645-0.957   0.003-0.389   0.423
  Body image                 0.628-0.826                                                    0.060-0.405                       0.715                         0.614-0.839   0.039-0.422   0.718   0.703-0.792   0.004-0.504   0.676

Two are missing.

Validity
--------

**Multitrait scaling analyses:** The correlations between all dimensions and their sub-items were higher than 0.4. In addition to the finding that the correlation between item 28 for the patients with a stoma and blood and mucus in stool dimension was 1, the correlations between other dimensions and their sub-items were all greater than their correlations with other items (Table [2](#T2){ref-type="table"}).

**Correlations with the EORTC QLQ-C30:** The dimensions and the single items included in the CR29 had correlations of 0.004-0.648 with the C30. Abdominal pain and pain showed a good correlation (*r* = 0.648), while the correlation between abdominal pain and fatigue was 0.411. The correlations between the anxiety dimension and the four dimensions of the C30 (role functioning, emotional functioning, social functioning and financial problems) were all greater than 0.4. The correlations between the blood and mucus in the stool dimension and three dimensions of the C30 (quality of life, pain and diarrhea) were all greater than 0.4. Seven dimensions (body image, buttock pain, hair loss, bloating, fecal incontinence, sore skin and dyspareunia) had correlation coefficients with nausea/vomiting that were higher than 0.4, and the correlations between the stool frequency and diarrhea as well as taste and appetite loss were also greater than 0.4 (Table [3](#T3){ref-type="table"}).

###### 

Correlations between the EORTC QLQ-CR29 and the QLQ-C30

                             **EORTC-QLQ-C30**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  -------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ----------------------------------------
  CR29 scales                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Urinary frequency          0.004                                    -0.071                                   -0.111[a](#T3FN1){ref-type="table-fn"}   -0.083                                   -0.163[b](#T3FN2){ref-type="table-fn"}   -0.159[b](#T3FN2){ref-type="table-fn"}   0.107[a](#T3FN1){ref-type="table-fn"}    -0.130[a](#T3FN1){ref-type="table-fn"}   -0.033                                   -0.046                                   0.061                                    0.023                                    -0.131[a](#T3FN1){ref-type="table-fn"}   -0.022                                   0.063
  Blood and mucus in stool   -0.412[b](#T3FN2){ref-type="table-fn"}   -0.320[b](#T3FN2){ref-type="table-fn"}   -0.074                                   -0.091                                   -0.166[b](#T3FN2){ref-type="table-fn"}   0.077                                    0.296[b](#T3FN2){ref-type="table-fn"}    0.383[b](#T3FN2){ref-type="table-fn"}    0.451[b](#T3FN2){ref-type="table-fn"}    0.166[b](#T3FN2){ref-type="table-fn"}    0.190[b](#T3FN2){ref-type="table-fn"}    0.120[a](#T3FN1){ref-type="table-fn"}    0.321[b](#T3FN2){ref-type="table-fn"}    0.526[b](#T3FN2){ref-type="table-fn"}    -0.141[a](#T3FN1){ref-type="table-fn"}
  Stool frequency            -0.322[b](#T3FN2){ref-type="table-fn"}   -0.236[b](#T3FN2){ref-type="table-fn"}   -0.075                                   -0.132[a](#T3FN1){ref-type="table-fn"}   -0.115[a](#T3FN1){ref-type="table-fn"}   -0.026                                   0.268[b](#T3FN2){ref-type="table-fn"}    0.340[b](#T3FN2){ref-type="table-fn"}    0.349[b](#T3FN2){ref-type="table-fn"}    0.212[b](#T3FN2){ref-type="table-fn"}    0.188[b](#T3FN2){ref-type="table-fn"}    0.120[a](#T3FN1){ref-type="table-fn"}    0.247[b](#T3FN2){ref-type="table-fn"}    0.492[b](#T3FN2){ref-type="table-fn"}    -0.113[a](#T3FN1){ref-type="table-fn"}
  Body image                 0.254[b](#T3FN2){ref-type="table-fn"}    0.179[b](#T3FN2){ref-type="table-fn"}    -0.052                                   0.051                                    0.100                                    -0.172[b](#T3FN2){ref-type="table-fn"}   -0.303[b](#T3FN2){ref-type="table-fn"}   -0.485[b](#T3FN2){ref-type="table-fn"}   -0.363[b](#T3FN2){ref-type="table-fn"}   -0.251[b](#T3FN2){ref-type="table-fn"}   -0.185[b](#T3FN2){ref-type="table-fn"}   -0.279[b](#T3FN2){ref-type="table-fn"}   -0.240[b](#T3FN2){ref-type="table-fn"}   -0.224[b](#T3FN2){ref-type="table-fn"}   0.132[a](#T3FN1){ref-type="table-fn"}
  CR29 single items                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Urinary incontinence       0.084                                    0.040                                    0.237[b](#T3FN2){ref-type="table-fn"}    0.203[b](#T3FN2){ref-type="table-fn"}    -0.071                                   0.171[b](#T3FN2){ref-type="table-fn"}    -0.038                                   0.270[b](#T3FN2){ref-type="table-fn"}    0.125[a](#T3FN1){ref-type="table-fn"}    0.311[b](#T3FN2){ref-type="table-fn"}    0.080                                    0.040                                    0.135[a](#T3FN1){ref-type="table-fn"}    0.139[b](#T3FN2){ref-type="table-fn"}    -0.291[b](#T3FN2){ref-type="table-fn"}
  Dysuria                    0.032                                    0.101                                    0.223[b](#T3FN2){ref-type="table-fn"}    0.210[b](#T3FN2){ref-type="table-fn"}    -0.185[b](#T3FN2){ref-type="table-fn"}   0.288[b](#T3FN2){ref-type="table-fn"}    0.053                                    0.330[b](#T3FN2){ref-type="table-fn"}    0.272[b](#T3FN2){ref-type="table-fn"}    0.296[b](#T3FN2){ref-type="table-fn"}    0.133[a](#T3FN1){ref-type="table-fn"}    0.003                                    0.279[b](#T3FN2){ref-type="table-fn"}    0.158[b](#T3FN2){ref-type="table-fn"}    -0.294[b](#T3FN2){ref-type="table-fn"}
  Abdominal pain             -0.357[b](#T3FN2){ref-type="table-fn"}   -0.399[b](#T3FN2){ref-type="table-fn"}   -0.149[b](#T3FN2){ref-type="table-fn"}   -0.086                                   -0.245[b](#T3FN2){ref-type="table-fn"}   0.097                                    0.411[b](#T3FN2){ref-type="table-fn"}    0.342[b](#T3FN2){ref-type="table-fn"}    0.648[b](#T3FN2){ref-type="table-fn"}    0.321[b](#T3FN2){ref-type="table-fn"}    0.307[b](#T3FN2){ref-type="table-fn"}    0.241[b](#T3FN2){ref-type="table-fn"}    0.375[b](#T3FN2){ref-type="table-fn"}    0.381[b](#T3FN2){ref-type="table-fn"}    -0.118[a](#T3FN1){ref-type="table-fn"}
  Buttock pain               -0.114[a](#T3FN1){ref-type="table-fn"}   -0.105                                   0.129[a](#T3FN1){ref-type="table-fn"}    0.056                                    -0.138[a](#T3FN1){ref-type="table-fn"}   0.271[b](#T3FN2){ref-type="table-fn"}    0.131[a](#T3FN1){ref-type="table-fn"}    0.487[b](#T3FN2){ref-type="table-fn"}    0.343[b](#T3FN2){ref-type="table-fn"}    0.224[b](#T3FN2){ref-type="table-fn"}    0.178[b](#T3FN2){ref-type="table-fn"}    0.139[b](#T3FN2){ref-type="table-fn"}    0.278[b](#T3FN2){ref-type="table-fn"}    0.160[b](#T3FN2){ref-type="table-fn"}    -0.273[b](#T3FN2){ref-type="table-fn"}
  Bloating                   -0.261[b](#T3FN2){ref-type="table-fn"}   -0.233[b](#T3FN2){ref-type="table-fn"}   -0.277[b](#T3FN2){ref-type="table-fn"}   -0.302[b](#T3FN2){ref-type="table-fn"}   -0.129[a](#T3FN1){ref-type="table-fn"}   -0.206[b](#T3FN2){ref-type="table-fn"}   0.213[b](#T3FN2){ref-type="table-fn"}    0.080                                    0.240[b](#T3FN2){ref-type="table-fn"}    0.130[a](#T3FN1){ref-type="table-fn"}    0.221[b](#T3FN2){ref-type="table-fn"}    0.183[b](#T3FN2){ref-type="table-fn"}    0.207[b](#T3FN2){ref-type="table-fn"}    0.252[b](#T3FN2){ref-type="table-fn"}    0.125[a](#T3FN1){ref-type="table-fn"}
  Dry mouth                  -0.117[a](#T3FN1){ref-type="table-fn"}   -0.074                                   0.181[b](#T3FN2){ref-type="table-fn"}    0.120[a](#T3FN1){ref-type="table-fn"}    -0.104                                   0.216[b](#T3FN2){ref-type="table-fn"}    0.152[b](#T3FN2){ref-type="table-fn"}    0.321[b](#T3FN2){ref-type="table-fn"}    0.262[b](#T3FN2){ref-type="table-fn"}    0.358[b](#T3FN2){ref-type="table-fn"}    0.134[a](#T3FN1){ref-type="table-fn"}    0.110[a](#T3FN1){ref-type="table-fn"}    0.218[b](#T3FN2){ref-type="table-fn"}    0.122[a](#T3FN1){ref-type="table-fn"}    -0.163[b](#T3FN2){ref-type="table-fn"}
  Hair loss                  -0.112[a](#T3FN1){ref-type="table-fn"}   -0.085                                   0.167[b](#T3FN2){ref-type="table-fn"}    0.037                                    -0.131[a](#T3FN1){ref-type="table-fn"}   0.222[b](#T3FN2){ref-type="table-fn"}    0.184[b](#T3FN2){ref-type="table-fn"}    0.486[b](#T3FN2){ref-type="table-fn"}    0.286[b](#T3FN2){ref-type="table-fn"}    0.276[b](#T3FN2){ref-type="table-fn"}    0.108[a](#T3FN1){ref-type="table-fn"}    0.127[a](#T3FN1){ref-type="table-fn"}    0.232[b](#T3FN2){ref-type="table-fn"}    0.155[b](#T3FN2){ref-type="table-fn"}    -0.200[b](#T3FN2){ref-type="table-fn"}
  Taste                      -0.218[b](#T3FN2){ref-type="table-fn"}   -0.238[b](#T3FN2){ref-type="table-fn"}   -0.214[b](#T3FN2){ref-type="table-fn"}   -0.278[b](#T3FN2){ref-type="table-fn"}   -0.222[b](#T3FN2){ref-type="table-fn"}   -0.107[a](#T3FN1){ref-type="table-fn"}   0.266[b](#T3FN2){ref-type="table-fn"}    0.137[a](#T3FN1){ref-type="table-fn"}    0.102                                    0.088                                    0.294[b](#T3FN2){ref-type="table-fn"}    0.459[b](#T3FN2){ref-type="table-fn"}    0.013                                    0.163[b](#T3FN2){ref-type="table-fn"}    0.083
  Anxiety                    -0.233[b](#T3FN2){ref-type="table-fn"}   -0.147[b](#T3FN2){ref-type="table-fn"}   -0.425[b](#T3FN2){ref-type="table-fn"}   -0.547[b](#T3FN2){ref-type="table-fn"}   -0.033                                   -0.412[b](#T3FN2){ref-type="table-fn"}   0.150[b](#T3FN2){ref-type="table-fn"}    -0.272[b](#T3FN2){ref-type="table-fn"}   -0.103                                   -0.095                                   0.011                                    0.134[a](#T3FN1){ref-type="table-fn"}    -0.089                                   0.066                                    0.449[b](#T3FN2){ref-type="table-fn"}
  Weight                     -0.217[b](#T3FN2){ref-type="table-fn"}   -0.266[b](#T3FN2){ref-type="table-fn"}   -0.346[b](#T3FN2){ref-type="table-fn"}   -0.371[b](#T3FN2){ref-type="table-fn"}   -0.175[b](#T3FN2){ref-type="table-fn"}   -0.244[b](#T3FN2){ref-type="table-fn"}   0.287[b](#T3FN2){ref-type="table-fn"}    0.042                                    0.103                                    0.026                                    0.202[b](#T3FN2){ref-type="table-fn"}    0.287[b](#T3FN2){ref-type="table-fn"}    0.005                                    0.184[b](#T3FN2){ref-type="table-fn"}    0.306[b](#T3FN2){ref-type="table-fn"}
  Flatulence                 -0.057                                   -0.094                                   0.170[b](#T3FN2){ref-type="table-fn"}    0.039                                    -0.115[a](#T3FN1){ref-type="table-fn"}   0.159[b](#T3FN2){ref-type="table-fn"}    0.092                                    0.433[b](#T3FN2){ref-type="table-fn"}    0.206[b](#T3FN2){ref-type="table-fn"}    0.180[b](#T3FN2){ref-type="table-fn"}    0.106[a](#T3FN1){ref-type="table-fn"}    0.180[b](#T3FN2){ref-type="table-fn"}    0.200[b](#T3FN2){ref-type="table-fn"}    0.236[b](#T3FN2){ref-type="table-fn"}    -0.166[b](#T3FN2){ref-type="table-fn"}
  Fecal incontinence         -0.017                                   -0.032                                   0.275[b](#T3FN2){ref-type="table-fn"}    0.218[b](#T3FN2){ref-type="table-fn"}    -0.129[a](#T3FN1){ref-type="table-fn"}   0.320[b](#T3FN2){ref-type="table-fn"}    0.049                                    0.447[b](#T3FN2){ref-type="table-fn"}    0.284[b](#T3FN2){ref-type="table-fn"}    0.252[b](#T3FN2){ref-type="table-fn"}    0.163[b](#T3FN2){ref-type="table-fn"}    0.055                                    0.229[b](#T3FN2){ref-type="table-fn"}    0.257[b](#T3FN2){ref-type="table-fn"}    -0.350[b](#T3FN2){ref-type="table-fn"}
  Sore skin                  -0.052                                   -0.132[a](#T3FN1){ref-type="table-fn"}   0.208[b](#T3FN2){ref-type="table-fn"}    0.170[b](#T3FN2){ref-type="table-fn"}    -0.094                                   0.296[b](#T3FN2){ref-type="table-fn"}    0.081                                    0.497[b](#T3FN2){ref-type="table-fn"}    0.205[b](#T3FN2){ref-type="table-fn"}    0.130[a](#T3FN1){ref-type="table-fn"}    0.160[b](#T3FN2){ref-type="table-fn"}    0.123[a](#T3FN1){ref-type="table-fn"}    0.106[a](#T3FN1){ref-type="table-fn"}    0.194[b](#T3FN2){ref-type="table-fn"}    -0.271[b](#T3FN2){ref-type="table-fn"}
  Embarrassment              -0.049                                   -0.041                                   0.200[b](#T3FN2){ref-type="table-fn"}    0.085                                    -0.019                                   0.209[b](#T3FN2){ref-type="table-fn"}    0.036                                    0.317[b](#T3FN2){ref-type="table-fn"}    0.167[b](#T3FN2){ref-type="table-fn"}    -0.006                                   0.027                                    0.059                                    0.070                                    0.088                                    -0.209[b](#T3FN2){ref-type="table-fn"}
  Stoma care problems        -0.184                                   0.210                                    0.224                                    -0.254                                   0.044                                    0.064                                    -0.025                                   0.019                                    -0.033                                   -0.265                                   -0.059                                   0.007                                    -0.161                                   0.073                                    0.175
  Sexual interest (men)      -0.108                                   -0.177[a](#T3FN1){ref-type="table-fn"}   -0.051                                   0.041                                    -0.276[b](#T3FN2){ref-type="table-fn"}   -0.184[b](#T3FN2){ref-type="table-fn"}   0.142[a](#T3FN1){ref-type="table-fn"}    -0.089                                   0.051                                    0.119                                    0.112                                    0.004                                    -0.010                                   0.039                                    0.092
  Impotence                  -0.026                                   -0.102                                   0.189[b](#T3FN2){ref-type="table-fn"}    0.177[a](#T3FN1){ref-type="table-fn"}    -0.212[b](#T3FN2){ref-type="table-fn"}   0.243[b](#T3FN2){ref-type="table-fn"}    0.105                                    0.242[b](#T3FN2){ref-type="table-fn"}    0.082                                    0.155[a](#T3FN1){ref-type="table-fn"}    0.175[a](#T3FN1){ref-type="table-fn"}    0.157[a](#T3FN1){ref-type="table-fn"}    0.069                                    0.093                                    -0.256[b](#T3FN2){ref-type="table-fn"}
  Sexual interest (women)    -0.319[b](#T3FN2){ref-type="table-fn"}   -0.213[a](#T3FN1){ref-type="table-fn"}   -0.092                                   0.030                                    -0.386[b](#T3FN2){ref-type="table-fn"}   -0.006                                   0.091                                    -0.099                                   0.044                                    0.194                                    0.270[b](#T3FN2){ref-type="table-fn"}    0.056                                    0.176                                    -0.010                                   0.215[a](#T3FN1){ref-type="table-fn"}
  Dyspareunia                0.026                                    0.003                                    0.213[b](#T3FN2){ref-type="table-fn"}    0.322[b](#T3FN2){ref-type="table-fn"}    -0.129                                   0.258[b](#T3FN2){ref-type="table-fn"}    -0.094                                   0.423[b](#T3FN2){ref-type="table-fn"}    0.185                                    0.227[a](#T3FN1){ref-type="table-fn"}    0.005                                    0.090                                    0.312[b](#T3FN2){ref-type="table-fn"}    0.117                                    -0.193

*P* \< 0.05,

*P* \< 0.01, EORTC QLQ-CR29 *vs* the QLQ-C30. QOL: Quality of life; PF: Physical functioning; RF: Role functioning; EF: Emotional functioning; CF: Cognitive functioning; SF: Social functioning; FA: Fatigue; NV: Nausea/vomiting; PA: Pain; DY: Dyspnea; SL: Insomnia; AP: Appetite loss; CO: Constipation; DI: Diarrhea; FI: Financial problems.

**Known-groups validity:** The differences between the CR29 and C30 scores are shown in Table [4](#T4){ref-type="table"}, where the data are grouped based on the clinical parameters. In addition to items such as abdominal pain, dry mouth and stoma care problems (0.059, 0.170, and 0.941) and dimensions such as urinary frequency and body image (0.098 and 0.589), other areas in subgroups divided by the KPS scores (KPS ≤ 80; KPS \> 80) also showed statistical significance (*P* \< 0.05). As for patients with or without a stoma, body image and most single-item dimensions from the CR29 and only role, social as well as nausea and vomiting dimensions from the C30 showed statistically significant differences.

###### 

Known group comparisons: scales and items in the QLQ-C30 and CR29 for clinically distinct groups

                             **Stoma (*n* = 56)**   **No stoma (*n* = 298)**   ***P* value[1](#T4FN1){ref-type="table-fn"}**   **KPS ≤ 80** **(*n* = 162)**   **KPS \> 80** **(*n* = 177)**   ***P* value[1](#T4FN1){ref-type="table-fn"}**
  -------------------------- ---------------------- -------------------------- ----------------------------------------------- ------------------------------ ------------------------------- -----------------------------------------------
  CR29 scales                                                                                                                                                                                 
  Urinary frequency          6.5 ± 14.5             6.1 ± 13.5                 0.856                                           6.7 ± 12.3                     5.8 ± 14.9                      0.098
  Blood and mucus in stool   18.9 ± 25.9            10.3 ± 16.3                0.160                                           13.8 ± 19.7                    7.3 ± 12.7                      0.019
  Stool frequency            8.0 ± 13.2             8.4 ± 14.8                 0.960                                           11.2 ± 18.2                    5.1 ± 9.6                       0.017
  Body image                 81.7 ± 18.9            88.6 ± 14.7                0.004                                           87.7 ± 17.7                    89.0 ± 11.9                     0.589
  CR29 single items                                                                                                                                                                           
  Urinary incontinence       7.7 ± 4.2              1.6 ± 7.1                  \< 0.001                                        0.8 ± 0.7                      4.2 ± 11.1                      0.001
  Dysuria                    7.7 ± 16.8             5.4 ± 12.3                 0.444                                           3.2 ± 11.2                     8.0 ± 14.7                      \< 0.001
  Abdominal pain             11.9 ± 21.5            12.0 ± 18.7                0.651                                           13.5 ± 21.0                    9.0 ± 16.1                      0.059
  Buttock pain               10.7 ± 15.7            5.4 ± 13.2                 0.005                                           2.5 ± 8.8                      9.0 ± 16.1                      \< 0.001
  Bloating                   16.1 ± 16.8            20.9 ± 21.4                0.183                                           25.2 ± 23.9                    15.0 ± 16.6                     \< 0.001
  Dry mouth                  11.9 ± 17.3            7.2 ± 15.1                 0.025                                           6.0 ± 14.4                     8.0 ± 15.1                      0.170
  Hair loss                  14.3 ± 18.9            9.6 ± 16.6                 0.058                                           7.7 ± 17.2                     11.1 ± 16.2                     0.010
  Taste                      15.5 ± 22.9            23.8 ± 21.7                0.002                                           26.0 ± 25.0                    18.8 ± 18.4                     0.015
  Anxiety                    31.0 ± 31.0            44.6 ± 23.7                \< 0.001                                        52.1 ± 22.6                    35.1 ± 24.1                     \< 0.001
  Weight                     22.6 ± 21.2            44.6 ± 23.7                0.032                                           32.3 ± 19.9                    21.6 ± 16.8                     \< 0.001
  Flatulence                 14.3 ± 17.8            5.0 ± 13.4                 \< 0.001                                        4.5 ± 14.6                     7.0 ± 13.6                      0.012
  Fecal incontinence         15.5 ± 20.1            4.4 ± 11.9                 \< 0.001                                        2.5 ± 10.2                     8.0 ± 15.1                      \< 0.001
  Sore skin                  26.2 ± 23.5            3.1 ± 10.1                 \< 0.001                                        3.5 ± 12.7                     9.7 ± 17.5                      \< 0.001
  Embarrassment              25.0 ± 20.4            2.3 ± 8.4                  \< 0.001                                        4.1 ± 12.8                     7.1 ± 14.6                      0.019
  Stoma care problems        /                      /                          /                                               18.8 ± 20.8                    19.8 ± 25.2                     0.941
  Sexual interest (men)      74.4 ± 23.5            69.8 ± 25.5                0.333                                           76.3 ± 22.8                    66.0 ± 26.0                     0.020
  Impotence                  9.4 ± 17.0             8.5 ± 20.2                 0.364                                           6.5 ± 19.2                     10.7 ± 19.9                     0.021
  Sexual interest (women)    81.0 ± 17.8            77.1 ± 22.5                0.749                                           83.7 ± 16.8                    71.2 ± 25.0                     0.005
  Dyspareunia                9.5 ± 16.3             4.3 ± 14.1                 0.172                                           2.7 ± 15.0                     6.5 ± 13.4                      0.012
  QLQ-C30 scales                                                                                                                                                                              
  Physical                   85.5 ± 12.4            82.9 ± 16.5                0.335                                           77.6 ± 18.3                    89.4 ± 10.7                     \< 0.001
  Role                       84.8 ± 17.2            69.4 ± 20.6                \< 0.001                                        61.7 ± 20.6                    81.2 ± 16.4                     \< 0.001
  Emotional                  80.5 ± 17.7            74.4 ± 14.0                0.001                                           69.3 ± 14.4                    81.2 ± 11.9                     \< 0.001
  Cognitive                  79.5 ± 20.5            80.7 ± 20.0                0.397                                           75.4 ± 34.9                    85.9 ± 14.6                     \< 0.001
  Social                     60.0 ± 22.4            45.7 ± 25.5                \< 0.001                                        38.5 ± 24.9                    55.7 ± 23.5                     \< 0.001
  Overall quality of life    67.9 ± 21.4            67.8 ± 17.4                0.636                                           59.5 ± 16.5                    76.4 ± 14.4                     \< 0.001
  Fatigue                    18.8 ± 18.2            22.8 ± 19.9                0.108                                           30.5 ± 20.3                    13.2 ± 13.8                     \< 0.001
  Nausea and vomiting        11.6 ± 13.8            6.1 ± 14.4                 \< 0.001                                        4.7 ± 15.7                     8.1 ± 12.5                      \< 0.001
  Pain                       13.0 ± 16.6            12.0 ± 17.3                0.427                                           13.3 ± 19.1                    9.4 ± 13.8                      0.211

Wilcoxon rank sum test.

Acceptability
-------------

In the survey, 285 of 356 patients (80.1%) completed the EORTC (C30 and CR29) questionnaires, and a total of 265 patients (74.4%) completed the basic status questionnaire and the measurement questionnaires. The lowest response rates were associated with sexual problems, with a miss rate of 3.4% (12 cases). Overall, the questionnaire completion rate was higher than 90%, which shows that over 90% of the items were answered.

DISCUSSION
==========

Due to improvements in curative therapy, doctors have started to pay more attention to HRQOL in CRC patients\[[@B13],[@B19]-[@B23]\]. In this study, we selected the EORTC QLQ-CR29 and EORTC QLQ-C30, and examined their reliability, validity, and acceptability in terms of assessing the quality of life in patients with CRC in mainland China. The overall goal of the study was to determine the feasibility of these instruments in the clinical setting in China.

The analysis of internal consistency showed that, regardless of whether a stoma was present, Cronbach's α coefficient in each dimension was satisfactory or near-satisfactory. In the original EORTC study, Cronbach's α coefficients were greater than or almost equal to 0.7\[[@B9]\]. Our data mainly showed lower Cronbach's α coefficients than those in a similar study by Nowak et al\[[@B8]\], particularly in the urinary frequency dimension (0.363-0.608). Of note, in the studies by Arraras et al\[[@B5]\], Nowak et al\[[@B8]\] and Arraras Urdaniz et al\[[@B24]\], Cronbach's α coefficients below 0.7 were also obtained for the abdominal pain and blood and mucus in the stool dimensions. The differences between our findings and those of previous studies may be due to differences in the perceptions of quality of life in patients from different regions; however, the differences were still in the acceptable range. In addition, the reliability of the dimensions related to body image and stool frequency in patients without a stoma was higher than that in patients with a stoma, which is different from the studies reported by Nowak et al\[[@B8]\] and Whistance et al\[[@B9]\].

In agreement with the results reported by Whistance, the correlations between the EORTC QLQ-CR29 items and their dimensions were greater than the correlation coefficients of other dimensions, suggesting that the EORTC QLQ-CR29 has great convergent validity and discriminant validity\[[@B9]\]. Item 28 was examined only in females. In this subgroup, there were 10 women, five of whom answered one survey, while the other five answered two surveys. The correlation coefficient between item 28 in the stoma group and the presence of blood and mucus in the stool was 1, probably due to the small number of cases in the sample. A similar finding was noted in the study by Arraras et al\[[@B5]\].

The correlation coefficients between the EORTC QLQ-CR29 and EORTC QLQ-C30 scales showed that similar dimensions of QLQ had high correlations, while unrelated dimensions were only weakly correlated, demonstrating the validity of the QLQ-CR29 and indicating that the two questionnaires had different points of emphasis.

A comparison of the results showed that there were different QLQ-CR29 dimension scores among the groups divided by the KPS scores (KPS ≤ 80; KPS \> 80) and whether the patients had a stoma or not, which signified that the QLQ-CR29 had good clinical validity and can be used to measure different patients with different conditions. These results are consistent with those reported by Whistance and other foreign validity tests\[[@B5],[@B8],[@B9]\]. In addition, this study showed that patients with a KPS \> 80 had higher scores in functional dimensions, but lower scores in the symptom dimensions, and those patients with a KPS ≤ 80 had a poorer quality of life. Statistically significant differences existed in numerous dimensions in groups divided by the KPS score *(e.g*., stool frequency, *P =* 0.017). Due to the impact of disease or treatment, sexual function in patients was significantly inhibited, similar to the findings in previous reports by other groups\[[@B5],[@B6],[@B24]\]. The studies by Song et al\[[@B25]\] and Peng et al\[[@B26]\] revealed that treatment of CRC may lead to impotence. However, this was not found in our study, probably because different countries perform different types of surgery, which result in different types of complications. In addition, compared with patients with a stoma, patients without a stoma had lower scores in the symptom dimensions, and higher scores in the functional dimensions, which indicated better quality of life. Moreover, in our study, the scope of the scores was wide in each dimension of the questionnaire, indicating that the Chinese version of the CR29 had good clinical validity.

People of different cultures often have a different understanding of quality of life. After adequate translation, the EORTC QLQ-CR29 was also proved to be suitable for Chinese patients. When Arraras performed research on a Spanish version of the survey, 4.7% of patients considered some of the items in the questionnaire to be difficult to understand or answer, or unrelated to quality of life\[[@B5]\]. In our study, few patients had such problems and there was a high compliance rate (with a low miss rate), both of which indicate that the Chinese version of the EORTC QLQ-CR29 had great acceptability. Compared with the studies by Arraras et al\[[@B5]\] and Whistance et al\[[@B9]\], the sexual dimension in our study had a higher miss rate (2.9% and 2.3% *vs* 3.4%). This may be due to the fact that Asians are more reticent when talking about sex than Western patients, and were not willing to tell the truth to doctors\[[@B26]\]. In order to address this problem and obtain a more accurate and comprehensive evaluation, a more detailed explanation from medical professionals is required when patients complete the questionnaire.

There are a few limitations in our study. Firstly, the subgroups were only segregated by the score on the Karnofsky Performance Scale, the presence of a stoma had more clinical significance than previously thought, and increased bias should not be ignored. In addition, the representativeness of our study should be treated cautiously due to the deficiency of larger cross-regional multicenter studies in mainland China. To obtain more rigorous results, we will pay more attention to these limitations in future studies.

In conclusion, the present study showed that the EORT QLQ-C29 (Chinese version) is a valid and reliable instrument for assessing the quality of life of patients with CRC in mainland China.

COMMENTS
========

Background
----------

Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer death. In 2012, almost 1.4 million people were diagnosed with CRC and 700 000 people died of CRC worldwide, of which China accounted for approximately 24%. Therefore, assessing and improving the quality of life of patients with CRC have become more important in these patients. The EORTC QLQ-CR29 questionnaire was developed by the European Organization for Research and Treatment of Cancer (EORTC) to evaluate quality of life in CRC patients.

Research frontiers
------------------

The EORTC QLQ-CR29 questionnaire has already been validated in Spain, Poland and several other countries. However, the dietary and cultural differences between China and Western countries may lead to different interpretations of quality of life. Therefore, it is essential to test the reliability and validity of the Chinese version of the EORTC QLQ-CR29 in patients with CRC, which has never been done in mainland China.

Innovations and breakthroughs
-----------------------------

In the past few decades, advances in medical technology have made it possible for CRC patients to live longer. More attention has been paid to the quality of life of these patients; thus, questionnaires that can accurately assess quality of life have been developed, of which the series of EORTC questionnaires play very important roles. The EORTC developed sub-questionnaires, including the core questionnaire QLQ-C30 for all cancers, the BR-23 for breast cancer, the CX-24 for cervical cancer and the CR-29 for CRC.

Applications
------------

Due to improvements in curative therapy, doctors have started to pay more attention to health-related quality of life in CRC patients. In this study, the authors selected the EORTC QLQ-CR29 and EORTC QLQ-C30 and examined their reliability, validity, and acceptability in terms of assessing the quality of life in patients with CRC in mainland China. The overall goal of the study was to determine the feasibility of these instruments in the clinical setting in China.

Terminology
-----------

The EORTC QLQ-C30 is the core questionnaire designed by the European Organization for Research and Treatment of Cancer, which can be used for all types of cancer. Based on the QLQ-C30, the EORTC QLQ-CR29 was specifically designed by the EORTC QL Group (The European Organization for Research and Treatment of Cancer Quality of Life Group) as a QLQ-C30 supplement for the evaluation of health-related quality of life in CRC patients.

Peer-review
-----------

By now, available papers have shown the EORTC QLQ-C30 combined the EORTC QLQ-CR29 can assess the quality of life of patients with CRC in Spanish, Polish and Malaysia. And this combination has already been widely used in both clinical and basic research.
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